Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $18.00.
A number of research firms have recently weighed in on MSLE. Zacks Research raised shares of Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Satellos Bioscience in a research report on Monday, May 18th. Cantor Fitzgerald began coverage on shares of Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating on the stock. Canaccord Genuity Group raised shares of Satellos Bioscience to a “moderate buy” rating in a research report on Thursday, May 21st. Finally, Leerink Partners began coverage on shares of Satellos Bioscience in a research report on Monday, April 6th. They issued an “outperform” rating and a $20.00 target price on the stock.
Read Our Latest Research Report on MSLE
Satellos Bioscience Stock Down 2.9%
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). Research analysts expect that Satellos Bioscience will post -2.26 EPS for the current year.
About Satellos Bioscience
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.
Recommended Stories
- Five stocks we like better than Satellos Bioscience
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
